May 15, 2025

Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer

In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and ...

The ASCO Post

May 15, 2025

Breast Parenchymal Phenotypes and Risk of Breast Cancer

Six parenchymal phenotypes were established that may be associated with a higher risk of developing breast cancer. Studies of these phenotypes identified by radiomics on mammograms demonstrated that t...

The ASCO Post

May 15, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical ...

The ASCO Post

May 14, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

May 14, 2025

Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases

In a phase II trial (PEACE V–STORM) reported in The Lancet Oncology, Ost et al evaluated whether elective nodal radiotherapy to the pelvis was associated with longer metastasis-free survival vs metast...

The ASCO Post

May 12, 2025

Annual or Biennial Multicancer Early Detection Screening Improves Patient Outcomes

The addition of multi-cancer early detection screening improved patient outcomes whether conducted on an annual or every 2-year basis, according to findings from a modelling study published in BMJ Ope...

The ASCO Post

May 12, 2025

Early-Onset Breast, Colorectal, Endometrial, Pancreatic, and Kidney Cancers on the Rise

A study by researchers at the National Cancer Institute investigating cancer incidence in the United States between 2010 and 2019 has found that breast, colorectal, endometrial, pancreatic, and kidney...

The ASCO Post

May 12, 2025

Effects of Tumor-Infiltrating Clonal Hematopoiesis

In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis was associated with an increased risk of death or recurrence among patients wi...

The ASCO Post

May 09, 2025

Off-the-Shelf Natural Killer CAR T-Cell Therapy Shows Efficacy in Small Study of Relapsed or Refractory Blood Cancers

The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia.1 Over the past decade, other...

The ASCO Post